Referências
Principais artigos
Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res (Hoboken). 2021 Aug;73(8):1088-105.Texto completo Resumo
Hellmich B, Sanchez-Alamo B, Schirmer JH, et al. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis. 2023 Mar 16:ard-2022-223764.Texto completo Resumo
Stone JH, Merkel PA, Spiera R, et al; RAVE-ITN Research Group. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010 Jul 15;363(3):221-32.Texto completo Resumo
Artigos de referência
1. Fauci AS, Haynes BF, Katz P, et al. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med. 1983 Jan;98(1):76-85. Resumo
2. Takala JH, Kautiainen H, Malmberg H, et al. Wegener's granulomatosis in Finland in 1981-2000: clinical presentation and diagnostic delay. Scand J Rheumatol. 2008 Nov-Dec;37(6):435-8. Resumo
3. Bajema IM, Hagen EC, van der Woude FJ, et al. Wegener's granulomatosis: a meta-analysis of 349 literary case reports. J Lab Clin Med. 1997 Jan;129(1):17-22. Resumo
4. Allenbach Y, Seror R, Pagnoux C, et al. High frequency of venous thromboembolic events in Churg-Strauss syndrome, Wegener's granulomatosis and microscopic polyangiitis but not polyarteritis nodosa: a systematic retrospective study on 1130 patients. Ann Rheum Dis. 2009 Apr;68(4):564-7. Resumo
5. Merkel PA, Lo GH, Holbrook JT, et al. Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study. Ann Intern Med. 2005 Apr 19;142(8):620-6. Resumo
6. Panupattanapong S, Stwalley DL, White AJ, et al. Epidemiology and outcomes of granulomatosis with polyangiitis in pediatric and working-age adult populations in the United States: analysis of a large national claims database. Arthritis Rheumatol. 2018 Dec;70(12):2067-76. Resumo
7. Pearce FA, Grainge MJ, Lanyon PC, et al. The incidence, prevalence and mortality of granulomatosis with polyangiitis in the UK Clinical Practice Research Datalink. Rheumatology (Oxford). 2017 Apr 1;56(4):589-96.Texto completo Resumo
8. Mohammad AJ, Jacobsson LT, Mahr AD, et al. Prevalence of Wegener's granulomatosis, microscopic polyangiitis, polyarteritis nodosa and Churg-Strauss syndrome within a defined population in southern Sweden. Rheumatology (Oxford). 2007 Aug;46(8):1329-37.Texto completo Resumo
9. Naidu GSRSNK, Misra DP, Rathi M, et al. Is granulomatosis with polyangiitis in Asia different from the West? Int J Rheum Dis. 2019 Jan;22(suppl 1):90-4. Resumo
10. Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med. 1992 Mar 15;116(6):488-98. Resumo
11. Koldingsnes W, Nossent H. Epidemiology of Wegener's granulomatosis in northern Norway. Arthritis Rheum. 2000 Nov;43(11):2481-7.Texto completo Resumo
12. Knight A, Ekbom A, Brandt L, et al. Increasing incidence of Wegener's granulomatosis in Sweden, 1975-2001. J Rheumatol. 2006 Oct;33(10):2060-3. Resumo
13. McKinney EF, Willcocks LC, Broecker V, et al. The immunopathology of ANCA-associated vasculitis. Semin Immunopathol. 2014 Jul;36(4):461-78.Texto completo Resumo
14. Knight A, Sandin S, Askling J. Risks and relative risks of Wegener's granulomatosis among close relatives of patients with the disease. Arthritis Rheum. 2008 Jan;58(1):302-7.Texto completo Resumo
15. Lyons PA, Rayner TF, Trivedi S, et al. Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med. 2012 Jul 19;367(3):214-23.Texto completo Resumo
16. Mahr AD, Neogi T, Merkel PA. Epidemiology of Wegener's granulomatosis: lessons from descriptive studies and analyses of genetic and environmental risk determinants. Clin Exp Rheumatol. 2006 Mar-Apr;24(2 Suppl 41):S82-91. Resumo
17. Stegeman CA, Tervaert JW, Sluiter WJ, et al. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med. 1994 Jan 1;120(1):12-7. Resumo
18. van der Woude FJ, Rasmussen N, Lobatto S, et al. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet. 1985 Feb 23;1(8426):425-9. Resumo
19. Fagin U, Csernok E, Müller A, et al. Distinct proteinase 3-induced cytokine patterns in Wegener´s granulomatosis, Churg-Strauss syndrome, and healthy controls. Clin Exp Rheumatol. 2011 Jan-Feb;29(1 suppl 64):S57-62. Resumo
20. Sneller MC. Rituximab and Wegener's granulomatosis: are B cells a target in vasculitis treatment? Arthritis Rheum. 2005 Jan;52(1):1-5.Texto completo Resumo
21. Robson JC, Grayson PC, Ponte C, et al. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis. Ann Rheum Dis. 2022 Mar;81(3):315-20. Resumo
22. Hunter RW, Welsh N, Farrah TE, et al. ANCA associated vasculitis. BMJ. 2020 Apr 14;369:m1070.Texto completo Resumo
23. Marroquín-Fabián E, Ruiz N, Mena-Zúñiga J, et al. Frequency, treatment, evolution, and factors associated with the presence of tracheobronchial stenoses in granulomatosis with polyangiitis. Retrospective analysis of a case series from a single respiratory referral center. Semin Arthritis Rheum. 2019 Feb;48(4):714-9. Resumo
24. Catano J, Uzunhan Y, Paule R, et al. Presentation, diagnosis, and management of subglottic and tracheal stenosis during systemic inflammatory diseases. Chest. 2022 Jan;161(1):257-65. Resumo
25. Singh S, Kaura D, Kumari S, et al. Wegener's presenting as submandibular swelling. Sarcoidosis Vasc Diffuse Lung Dis. 1997 Mar;14(1):81-2. Resumo
26. Holl-Ulrich K, Klass M. Wegener's granulomatosis with granulomatous liver involvement. Clin Exp Rheumatol. 2010 Jan-Feb;28(1 suppl 57):88-9. Resumo
27. Papaioannides D, Nikas SN, Fotinou M, et al. Asymptomatic splenic infarction in Wegener's granulomatosis. Ann Rheum Dis. 2002 Feb;61(2):185-6.Texto completo Resumo
28. Bossuyt X, Cohen Tervaert JW, Arimura Y, et al. Position paper: revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis. Nat Rev Rheumatol. 2017 Nov;13(11):683-92.Texto completo Resumo
29. Cornec D, Cornec-Le Gall E, Fervenza FC, et al. ANCA-associated vasculitis - clinical utility of using ANCA specificity to classify patients. Nat Rev Rheumatol. 2016 Oct;12(10):570-9. Resumo
30. Damoiseaux J, Csernok E, Rasmussen N, et al. Detection of antineutrophil cytoplasmic antibodies (ANCAs): a multicentre European Vasculitis Study Group (EUVAS) evaluation of the value of indirect immunofluorescence (IIF) versus antigen-specific immunoassays. Ann Rheum Dis. 2017 Apr;76(4):647-53. Resumo
31. Finkielman JD, Lee AS, Hummel AM, et al. ANCA are detectable in nearly all patients with active severe Wegener's granulomatosis. Am J Med. 2007 Jul;120(7):643.e9-14.Texto completo Resumo
32. Finkielman JD, Merkel PA, Schroeder D, et al; WGET Research Group. Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis. Ann Intern Med. 2007 Nov 6;147(9):611-9. Resumo
33. Lohrmann C, Uhl M, Kotter E, et al. Pulmonary manifestations of wegener granulomatosis: CT findings in 57 patients and a review of the literature. Eur J Radiol. 2005 Mar;53(3):471-7. Resumo
34. Lohrmann C, Uhl M, Warnatz K, et al. Sinonasal computed tomography in patients with Wegener's granulomatosis. J Comput Assist Tomogr. 2006 Jan-Feb;30(1):122-5. Resumo
35. Veerysami M, Freeth M, Carmichael AR, et al. Wegener's granulomatosis of the breast. Breast J. 2006 May-Jun;12(3):268-70. Resumo
36. Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Arthritis Rheum. 2013 Jan;65(1):1-11. Resumo
37. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res (Hoboken). 2021 Aug;73(8):1088-105.Texto completo Resumo
38. Hellmich B, Sanchez-Alamo B, Schirmer JH, et al. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis. 2023 Mar 16:ard-2022-223764.Texto completo Resumo
39. Langford CA, Talar-Williams C, Barron KS, et al. A staged approach to the treatment of Wegener's granulomatosis: induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance. Arthritis Rheum. 1999 Dec;42(12):2666-73.Texto completo Resumo
40. Walton EW. Giant-cell granuloma of the respiratory tract (Wegener's granulomatosis). Br Med J. 1958 Aug 2;2(5091):265-70.Texto completo Resumo
41. Walsh M, Merkel PA, Peh CA, et al. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N Engl J Med. 2020 Feb 13;382(7):622-31.Texto completo Resumo
42. Jayne DRW, Merkel PA, Schall TJ, et al. Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med. 2021 Feb 18;384(7):599-609.Texto completo Resumo
43. American College of Rheumatology. 2022 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Jul 2023 [internet publication].Texto completo
44. National Institute for Health and Care Excellence. Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis. Sep 2022 [internet publication].Texto completo
45. Stone JH, Merkel PA, Spiera R, et al; RAVE-ITN Research Group. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010 Jul 15;363(3):221-32.Texto completo Resumo
46. Jones RB, Tervaert JW, Hauser T, et al; European Vasculitis Study Group. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010 Jul 15;363(3):211-20. Resumo
47. Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003 Jul 3;349(1):36-44.Texto completo Resumo
48. De Groot K, Rasmussen N, Bacon PA, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2005 Aug;52(8):2461-9.Texto completo Resumo
49. De Groot K, Harper L, Jayne DR, et al; EUVAS (European Vasculitis Study Group). Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med. 2009 May 19;150(10):670-80. Resumo
50. Harper L, Morgan MD, Walsh M, et al. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann Rheum Dis. 2012 Jun;71(6):955-60. Resumo
51. Jayne DR, Gaskin G, Rasmussen N, et al; European Vasculitis Study Group. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol. 2007 Jul;18(7):2180-8.Texto completo Resumo
52. Shemin D, Briggs D, Greenan M. Complications of therapeutic plasma exchange: a prospective study of 1,727 procedures. J Clin Apher. 2007;22(5):270-6. Resumo
53. Sammaritano LR, Bermas BL, Chakravarty EE, et al. 2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. Arthritis Rheumatol. 2020 Apr;72(4):529-56.Texto completo Resumo
54. Jones RB, Hiemstra TF, Ballarin J, et al. Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial. Ann Rheum Dis. 2019 Mar;78(3):399-405.Texto completo Resumo
55. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med. 2005 Jan 27;352(4):351-61.Texto completo Resumo
56. Guillevin L, Pagnoux C, Karras A, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014 Nov 6;371(19):1771-80. Resumo
57. Ho C, Adcock L. Rituximab maintenance therapy for the management of granulomatosis with polyangiitis or microscopic polyangiitis: a review of clinical effectiveness, cost-effectiveness, and guidelines. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Jul 31.Texto completo Resumo
58. Clinicaltrials.gov. Rituximab vasculitis maintenance study (RITAZAREM). NCT01697267. Mar 2022 [internet publication].Texto completo
59. Charles P, Perrodeau É, Samson M, et al. Long-term rituximab use to maintain remission of antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med. 2020 Aug 4;173(3):179-87. Resumo
60. Tieu J, Smith R, Basu N, et al. Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines. Rheumatology (Oxford). 2020 Apr 1;59(4):e24-e32.Texto completo Resumo
61. Pagnoux C, Mahr A, Hamidou MA, et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med. 2008 Dec 25;359(26):2790-803.Texto completo Resumo
62. Hiemstra TF, Walsh M, Mahr A, et al; European Vasculitis Study Group (EUVAS). Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA. 2010 Dec 1;304(21):2381-8. Resumo
63. Walsh M, Merkel PA, Mahr A, et al. Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis. Arthritis Care Res (Hoboken). 2010 Aug;62(8):1166-73.Texto completo Resumo
64. National Institute for Health and Care Excellence. Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis. Mar 2014 [internet publication].Texto completo
65. Langford CA, Sneller MC, Hallahan CW, et al. Clinical features and therapeutic management of subglottic stenosis in patients with Wegener's granulomatosis. Arthritis Rheum. 1996 Oct;39(10):1754-60. Resumo
66. Langford CA, Monach PA, Specks U, et al; Vasculitis Clinical Research Consortium. An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener's). Ann Rheum Dis. 2014 Jul;73(7):1376-9. Resumo
67. Flossmann O, Jayne DR. Long-term treatment of relapsing Wegener's granulomatosis with 15-deoxyspergualin. Rheumatology (Oxford). 2010 Mar;49(3):556-62.Texto completo Resumo
68. Little MA, Nightingale P, Verburgh CA, et al; European Vasculitis Study (EUVAS) Group. Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis. 2010 Jun;69(6):1036-43. Resumo
69. Mohammad AJ, Jacobsson LT, Westman KW, et al. Incidence and survival rates in Wegener's granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and polyarteritis nodosa. Rheumatology (Oxford). 2009 Dec;48(12):1560-5. Resumo
70. Seo P, Min YI, Holbrook JT, et al; WGET Research Group. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial. Arthritis Rheum. 2005 Jul;52(7):2168-78.Texto completo Resumo
71. Flossmann O, Berden A, de Groot K, et al; European Vasculitis Study Group. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis. 2011 Mar;70(3):488-94. Resumo
72. de Leeuw K, Sanders JS, Stegeman C, et al. Accelerated atherosclerosis in patients with Wegener's granulomatosis. Ann Rheum Dis. 2005 May;64(5):753-9.Texto completo Resumo
73. Knight A, Askling J, Ekbom A. Cancer incidence in a population-based cohort of patients with Wegener's granulomatosis. Int J Cancer. 2002 Jul 1;100(1):82-5.Texto completo Resumo
74. Hellmich B, Kausch I, Doehn C, et al. Urinary bladder cancer in Wegener's granulomatosis: is it more than cyclophosphamide? Ann Rheum Dis. 2004 Oct;63(10):1183-5.Texto completo Resumo
75. Faurschou M, Mellemkjaer L, Voss A, et al. Prolonged risk of specific malignancies following cyclophosphamide therapy among patients with granulomatosis with polyangiitis. Rheumatology (Oxford). 2015 Aug;54(8):1345-50.Texto completo Resumo
76. Bakthavachalam S, Driver MS, Cox C, et al. Hearing loss in Wegener's granulomatosis. Otol Neurotol. 2004 Sep;25(5):833-7. Resumo
77. Stone JH, Hoffman GS, Merkel PA, et al; International Network for the Study of the Systemic Vasculitides (INSSYS). A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. Arthritis Rheum. 2001 Apr;44(4):912-20. Resumo
78. Exley AR, Bacon PA, Lugmani RA, et al. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum. 1997 Feb;40(2):371-80. Resumo
O uso deste conteúdo está sujeito ao nosso aviso legal